share_log

Why You Might Be Interested In Sinopharm Group Co. Ltd. (HKG:1099) For Its Upcoming Dividend

Why You Might Be Interested In Sinopharm Group Co. Ltd. (HKG:1099) For Its Upcoming Dividend

为什么您会对国药控股股份有限公司(HKG:1099)即将派发的股息感兴趣
Simply Wall St ·  2022/06/22 05:38

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Sinopharm Group Co. Ltd. (HKG:1099) is about to trade ex-dividend in the next four days. The ex-dividend date is one business day before a company's record date, which is the date on which the company determines which shareholders are entitled to receive a dividend. It is important to be aware of the ex-dividend date because any trade on the stock needs to have been settled on or before the record date. This means that investors who purchase Sinopharm Group's shares on or after the 27th of June will not receive the dividend, which will be paid on the 23rd of August.

老读者会知道我们喜欢Simply Wall St.的红利,这就是为什么看到国药控股股份有限公司。(HKG:1099)即将在未来四天内进行除股息交易。除息日期是公司记录日期的前一个工作日,也就是公司决定哪些股东有权获得股息的日期。重要的是要知道除息日期,因为股票的任何交易都需要在记录日期或之前结算。这意味着,在6月27日或之后购买国药控股股票的投资者将不会收到股息,股息将在8月23日支付。

The company's next dividend payment will be CN¥0.75 per share, on the back of last year when the company paid a total of CN¥0.75 to shareholders. Based on the last year's worth of payments, Sinopharm Group has a trailing yield of 4.6% on the current stock price of HK$19.06. Dividends are a major contributor to investment returns for long term holders, but only if the dividend continues to be paid. That's why we should always check whether the dividend payments appear sustainable, and if the company is growing.

该公司下一次派息将为每股0.75元人民币,而去年公司向股东支付的股息总额为0.75元人民币。根据上一年的支付金额,国药控股目前的股价为19.06港元,往绩收益率为4.6%。股息是长期持有者投资回报的主要贡献者,但前提是继续支付股息。这就是为什么我们应该总是检查股息支付是否看起来可持续,以及公司是否在增长。

Check out our latest analysis for Sinopharm Group

看看我们对国药控股的最新分析

If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. That's why it's good to see Sinopharm Group paying out a modest 29% of its earnings. Yet cash flows are even more important than profits for assessing a dividend, so we need to see if the company generated enough cash to pay its distribution. Thankfully its dividend payments took up just 39% of the free cash flow it generated, which is a comfortable payout ratio.

如果一家公司支付的股息超过了它赚取的股息,那么股息可能会变得不可持续--这几乎不是一个理想的情况。这就是为什么看到国药控股只支付其收益的29%是件好事。然而,对于评估股息而言,现金流甚至比利润更重要,因此我们需要看看公司是否产生了足够的现金来支付分配。值得庆幸的是,它的股息支付仅占其产生的自由现金流的39%,这是一个令人满意的派息率。

It's positive to see that Sinopharm Group's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut.

看到国药控股的股息同时由利润和现金流覆盖,这是积极的,因为这通常是股息可持续的迹象,较低的派息率通常意味着在股息削减之前有更大的安全边际。

Click here to see the company's payout ratio, plus analyst estimates of its future dividends.

点击此处查看该公司的派息率,以及分析师对其未来股息的估计。

SEHK:1099 Historic Dividend June 22nd 2022
联交所:1099历史股息2022年6月22日

Have Earnings And Dividends Been Growing?

盈利和股息一直在增长吗?

Businesses with strong growth prospects usually make the best dividend payers, because it's easier to grow dividends when earnings per share are improving. Investors love dividends, so if earnings fall and the dividend is reduced, expect a stock to be sold off heavily at the same time. This is why it's a relief to see Sinopharm Group earnings per share are up 8.7% per annum over the last five years. Management have been reinvested more than half of the company's earnings within the business, and the company has been able to grow earnings with this retained capital. We think this is generally an attractive combination, as dividends can grow through a combination of earnings growth and or a higher payout ratio over time.

增长前景强劲的企业通常是最好的股息支付者,因为当每股收益改善时,增加股息更容易。投资者喜欢分红,所以如果收益下降,股息减少,预计一只股票将同时被大量抛售。这就是为什么看到国药控股的每股收益在过去五年里以每年8.7%的速度增长,这让人松了一口气。管理层已将公司一半以上的收益再投资于业务,公司能够利用这些留存资本增长收益。我们认为,这通常是一个有吸引力的组合,因为随着时间的推移,股息可以通过收益增长和/或更高的派息率来增长。

Another key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. Since the start of our data, 10 years ago, Sinopharm Group has lifted its dividend by approximately 15% a year on average. We're glad to see dividends rising alongside earnings over a number of years, which may be a sign the company intends to share the growth with shareholders.

衡量一家公司股息前景的另一个关键方法是衡量其历史股息增长率。自10年前开始我们的数据以来,国药控股的股息平均每年增加约15%。我们很高兴看到多年来股息随着收益的增加而上升,这可能是该公司打算与股东分享增长的迹象。

The Bottom Line

底线

Is Sinopharm Group an attractive dividend stock, or better left on the shelf? Earnings per share have been growing moderately, and Sinopharm Group is paying out less than half its earnings and cash flow as dividends, which is an attractive combination as it suggests the company is investing in growth. It might be nice to see earnings growing faster, but Sinopharm Group is being conservative with its dividend payouts and could still perform reasonably over the long run. Overall we think this is an attractive combination and worthy of further research.

国药控股是一只有吸引力的分红股,还是更好地被搁置?每股收益一直在温和增长,国药控股只支付了不到一半的收益和现金流作为股息,这是一个有吸引力的组合,因为它表明该公司正在投资于增长。盈利增长更快可能是件好事,但国药控股对股息支出持保守态度,长期而言仍有可能表现合理。总体而言,我们认为这是一个有吸引力的组合,值得进一步研究。

With that in mind, a critical part of thorough stock research is being aware of any risks that stock currently faces. Our analysis shows 1 warning sign for Sinopharm Group and you should be aware of it before buying any shares.

考虑到这一点,彻底的股票研究的一个关键部分是意识到股票目前面临的任何风险。我们的分析显示国药控股的1个警示标志在购买任何股票之前,你应该意识到这一点。

Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.

一般来说,我们不会建议只购买你看到的第一批股息股票。这是这是一份精心挑选的股息支付强劲的有趣股票的名单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发